Cao Da-Long, Yao Xu-Dong
Department of Urology, Cancer Hospital, Fudan University, Shanghai 200032, PR China.
Chin J Cancer. 2010 Feb;29(2):229-33. doi: 10.5732/cjc.009.10274.
More and more studies have revealed that the level of serum prostate specific antigen(PSA) has little value for early diagnosis of prostate cancer (PCa). For example, negative prostate biopsies are as high as 70%-80% for patients with serum PSA ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the early diagnosis of PCa, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives, HPC1, PCA3, TMPRSS2: ETS, GSTP1, AMACR, GOLPH2, EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the early diagnosis and the prognostic monitoring of patients with PCa.
越来越多的研究表明，血清前列腺特异性抗原（PSA）水平对前列腺癌（PCa）的早期诊断价值不大。例如，血清PSA在4 ng/mL至10 ng/mL之间的患者，前列腺穿刺活检阴性率高达70%-80%。然而，阴性结果并不能排除癌症的存在。在PCa早期诊断的研究中，研究者们致力于寻找具有更高敏感性和特异性的生物标志物。近年来，PSA衍生物、HPC1、PCA3、TMPRSS2:ETS、GSTP1、AMACR、GOLPH2、EPCA、肌氨酸以及多种生物标志物的组合受到广泛讨论。在本文中，我们综述了它们的最新进展以及多种生物标志物组合的潜在价值，这可能有助于PCa患者的早期诊断和预后监测。
